Michigan Emergency Department Improvement Collaborative AltERnaTives to admission for Pulmonary Embolism (MEDIC ALERT PE) Study

密歇根急诊科改进合作入院肺栓塞 (MEDIC ALERT PE) 研究

基本信息

项目摘要

PROJECT SUMMARY Of the 250,000 annual patients in the United States with acute pulmonary embolism (PE), the majority are at low risk for morbidity and mortality. In fact, evidence-based guidelines suggest that up to 50% of patients with an acute PE are at sufficiently low risk for complications that they can be safely managed without hospital admission. Yet fewer than 5% of patients nation-wide are currently discharged for outpatient management. Reliable access to anticoagulant medications and outpatient follow-up are commonly cited barriers to outpatient management. However, prevailing heuristics used by Emergency Medicine clinicians to enable rapid decision-making also firmly link acute PE with hospital admission, and likely makes behavior change for these busy clinicians more challenging. Multiple prior efforts to reduce hospital admission for low-risk patients with acute PE have been limited by single-center designs, inclusion of homogenous and highly-resourced health systems, or have lacked a robust implementation plan underpinning to their design and evaluation. Using the diverse, state-wide Michigan Emergency Department Improvement Collaborative (MEDIC), we will refine, tailor, and evaluate a multi-component intervention suitable for broad dissemination to increase the use of outpatient management of low-risk acute PE for patients presenting to the emergency department. Following an implementation mapping approach built upon published literature and our preliminary findings, our intervention will address key barriers identified by a diverse group of stakeholders by combining traditional implementation science and behavioral economics strategies. Importantly, electronic alerts will be informed by user-centered design approaches to fit within the clinician workflow and decision-making process and “right sized” to appear only for applicable patients. Evaluation will include both quantitative and qualitative elements from the RE-AIM implementation evaluation framework. This multi-component intervention will facilitate a patient-centered approach to clinical decision-making that improves value by reducing unnecessary hospitalization for patients with low-risk PE. Furthermore, by tailoring and evaluating this intervention within a diverse set of hospitals, our multi-component intervention will be well positioned for dissemination nation-wide. Finally, our use of multi-site implementation mapping will provide a blueprint for other multi-site collaboratives interested in improving outcomes for a broad array of clinical conditions through rigorous quality improvement and implementation initiatives.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Geoffrey Douglas Barnes其他文献

Geoffrey Douglas Barnes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Geoffrey Douglas Barnes', 18)}}的其他基金

Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
为循证抗凝药物的使用实施处方者-药剂师协作护理
  • 批准号:
    10487496
  • 财政年份:
    2021
  • 资助金额:
    $ 70.82万
  • 项目类别:
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
为循证抗凝药物的使用实施处方者-药剂师协作护理
  • 批准号:
    10705628
  • 财政年份:
    2021
  • 资助金额:
    $ 70.82万
  • 项目类别:
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
为循证抗凝药物的使用实施处方者-药剂师协作护理
  • 批准号:
    10330852
  • 财政年份:
    2021
  • 资助金额:
    $ 70.82万
  • 项目类别:
Improving Safe Use of Direct Oral Anticoagulants: A Population Health Approach
提高直接口服抗凝剂的安全使用:人口健康方法
  • 批准号:
    10373967
  • 财政年份:
    2020
  • 资助金额:
    $ 70.82万
  • 项目类别:
Development of computer aided decision support and EHR alerts for DOAC prescribing
开发用于 DOAC 处方的计算机辅助决策支持和 EHR 警报
  • 批准号:
    10221047
  • 财政年份:
    2020
  • 资助金额:
    $ 70.82万
  • 项目类别:
Development of computer aided decision support and EHR alerts for DOAC prescribing
开发用于 DOAC 处方的计算机辅助决策支持和 EHR 警报
  • 批准号:
    10059571
  • 财政年份:
    2020
  • 资助金额:
    $ 70.82万
  • 项目类别:
Developing an Implementation Strategy to Improve Peri-procedural Anticoagulation Management for Patients with Atrial Fibrillation
制定实施策略以改善心房颤动患者的围手术期抗凝管理
  • 批准号:
    9222184
  • 财政年份:
    2017
  • 资助金额:
    $ 70.82万
  • 项目类别:
Developing an Implementation Strategy to Improve Peri-procedural Anticoagulation Management for Patients with Atrial Fibrillation
制定实施策略以改善心房颤动患者的围手术期抗凝管理
  • 批准号:
    10079024
  • 财政年份:
    2017
  • 资助金额:
    $ 70.82万
  • 项目类别:
Training to Advance Care Through Implementation Science in Cardiac And Lung Illnesses (TACTICAL)
通过在心脏和肺部疾病中实施科学来推进护理的培训(战术)
  • 批准号:
    10204091
  • 财政年份:
    2017
  • 资助金额:
    $ 70.82万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 70.82万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了